AUTHORS
Utsav Joshi, MD, Anish Shah, MD2, Vishakha Agrawal3, Chengu Niu4, Zhuoer Xie, MD,MS5, Seongseok Yun, MD, PhD6, Rory Shallis I, MD7, Andrew T Kuykendall, MD8, Alison Walker, MD9, David Sallman, MD10, Eric Padron, MD11, Rami Komrokji, MD12, Jeffrey Lancet, MD13, Onyee Chan, MD14
AFFILIATIONS
1 Moffitt Cancer Center, Tampa, Florida, United States
2 Moffitt Cancer Center, Tampa, Florida, United States
3 University of South Florida, Tampa, United States
4 University of Nebraska, Omaha, United States
5 Moffitt Cancer Center, Tampa, Florida, United States
6 Moffitt Cancer Center, Tampa, Florida, United States
7 Moffitt Cancer Center, Tampa, Florida, United States
8 Moffitt Cancer Center, Tampa, Florida, United States
9 Moffitt Cancer Center, Tampa, Florida, United States
10 Moffitt Cancer Center, Tampa, Florida, United States
11 Moffitt Cancer Center, Tampa, Florida, United States
12 Moffitt Cancer Center, Tampa, Florida, United States
13 Moffitt Cancer Center, Tampa, Florida, United States
14 Moffitt Cancer Center, Tampa, Florida, United States
ABSTRACT
Background: Although blast-phase myeloproliferative neoplasms (MPN-BP) are associated with poor outcomes, the ideal treatment intensity in the era of venetoclax-based therapy remains uncertain.
Methods: This retrospective cohort study used the TriNetX database to identify patients ≥65 years with MPN-BP from 2015 to 2025 (N=1031). Two mutually exclusive treatment cohorts were constructed using ICD-10 and medication codes: the intensive cohort (IC; N=337) received cytarabine combined with daunorubicin, idarubicin, fludarabine, mitoxantrone, midostaurin, or gemtuzumab ozogamicin, and the lower-intensity cohort (LI; N=694) received venetoclax combined with either azacitidine or decitabine. Patients with prior chronic myeloid leukemia were excluded; cladribine-treated patients were excluded because cytarabine dose could not be distinguished in combination regimens. Cohorts were balanced for age, sex, race, and comorbidities using propensity score matching (N=226 each). Patient demographics, early mortality, remission rate, overall survival, and post-treatment complications were assessed. OS was calculated from treatment initiation to death.
Results: The mean age at diagnosis was 68 years in both cohorts, and most patients were male and White. Comorbidities were similarly distributed between groups, including ischemic heart disease (26% vs 27%), cerebrovascular disease (14% vs 12%), chronic kidney disease (21% vs 16%), and diabetes (27% vs 26%). Baseline labs included WBC (40.8 ± 315 vs 47.5 ± 360/µL), hemoglobin (8.5 ± 2 vs 8.5 ± 1.7 gm/dL), platelet count (129 ± 190.3 vs 146 ± 295/µL), and marrow blast percent (19.6 ± 14.7 vs 25.4 ± 23.4). Among 452 unique patients, 39.6% PV/ET, 48.2% primary myelofibrosis, and 28.8% post-PV/ET myelofibrosis transformed to AML (exceeds 100% due to multiple MPN diagnosis codes per patient over time).
The median follow-up was 11.6 months (IC) vs. 8.4 months (LI). 30-day mortality was 9.8% (IC) vs 7.1% (LI), RR 1.38, 95% CI 0.75-2.56, and 60-day mortality was 13.8% (IC) vs. 17.8% (LI), RR 0.78, 95% CI 0.51-1.2. Remission occurred more frequently in IC (53% vs 30%, RR 1.76, 95% CI 1.37-2.26). One-year OS was 47.96% (IC) vs. 40.44% (LI) (p=0.03). Median OS was 11.4 (IC) vs 6.7 months (LI) (p <0.001, HR 0.68, 95% CI 0.54-0.86). When we excluded allogeneic transplant recipients (N=152 per cohort), median OS was 8.9 (IC) vs 5.6 months (LI) (p=0.005; HR 0.68, 95% CI 0.51-0.89). Post-induction adverse events were similar between cohorts for heart failure (18% vs 25%; RR 0.72, 95% CI 0.49-1.07) and sepsis (35.4% vs 34.3%; RR 1.03, 95% CI 0.77 - 1.38). Acute kidney injury was more frequent in IC (43.5% vs 29.2%; RR 1.49, 95% CI 1.08-2.06).
Conclusion: IC was associated with higher remission rates and significantly improved OS compared with LI, without increased early mortality. These findings suggest a potential survival benefit with intensive treatment; however, validation in larger cohorts with detailed molecular characterization is needed to confirm these observations.
DISCLOSURES
Utsav Joshi, MD: No relevant conflicts of interest to declare.